Benzonatate (Benzonatate) , a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26-nonaoxaoctacosan-28-yl p-(butylamino) benzoate; with a molecular weight of 603.00 (av).

Each capsule, for oral administration, contains 150 mg of Benzonatate (Benzonatate) , USP.

In addition, each capsule contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose cellulose, hydroxypropyl cellulose, microcrystalline cellulose, and silicon dioxide. Capsule shell is composed of gelatin, titanium dioxide, FD&C Blue #1 and D&C Red #28. Imprinting ink is composed of black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac and strong ammonia solution.

Benzonatate (Benzonatate) acts peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate (Benzonatate) has no inhibitory effect on the respiratory center in recommended dosage.

ZONATUSS (Benzonatate (Benzonatate) capsules, USP) is indicated for the symptomatic relief of cough.

Hypersensitivity to Benzonatate (Benzonatate) or related compounds.

Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures. Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking Benzonatate (Benzonatate) in combination with other prescribed drugs.

Benzonatate (Benzonatate) is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g., procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.

Potential Adverse Reactions to Benzonatate (Benzonatate) may include:

Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.

Rare instances of deliberate or accidental overdose have resulted in death.

Overdose may result in death.

The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.

If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly. CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression.

Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.

Do not use CNS stimulants.

Adults and Children over 10: Usual dose is one 150 mg capsule three times daily as required. If necessary, up to 600 mg daily may be given.

ZONATUSS (Benzonatate (Benzonatate) capsules USP, 150 mg) is supplied as opaque white body and opaque light blue cap imprinted "150" on the body and "ZON" on the cap, in black ink, in bottles of 100 capsules, NDC 59702-150-01 and in unit dose sample pouches for patient trial available only through physician offices, NDC 59702-150-12.

Store at 20º to 25º C (68º to 77ºF) [see USP Controlled Room Temperature].

Protect From Light

Dispense in a tight, light-resistant container as defined in the USP. Keep tightly closed.

Manufactured for:

Ashland, VA 23005

Manufactured by:

Atlanta, Georgia 30318

Code 1006B00

Rev. 10/09

NDC 59702-150-01

100 Capsules

ZONATUSS

(Benzonatate (Benzonatate) Capsules, USP)

U.S. Patents Pending

Rx only

150 mg

Atley

NDC 59702-150-12

One Capsule

ZONATUSS

(Benzonatate (Benzonatate) Capsule, USP)

Rx only

150 mg

Physician Sample

Not for resale

This package is not child-resistant

Code 1006B21-F

Rev. 10/09